FDA Slow Walking a Long-Awaited Abortion Pill Safety Study (2)

The Food and Drug Administration has delayed a promised review of safety data for the abortion drug mifepristone at Commissioner Marty Makary’s request to put it off until after the midterm elections, according to people familiar with the matter.

Makary and Health and Human Services Secretary Robert F. Kennedy Jr. have told lawmakers and state attorneys general for months that they are actively conducting a review of mifepristone. But behind the scenes, Makary has told agency officials to delay the safety review, people familiar with the discussions said.

“Assertions that the FDA is slow walking this review for political ...